# Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

> **NCT06516887** · PHASE1,PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 44 (estimated)

## Conditions studied

- Advanced Lung Adenocarcinoma

## Interventions

- **DRUG:** bemcentinib
- **DRUG:** pacritinib

## Key facts

- **NCT ID:** NCT06516887
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-27
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516887, "Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06516887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*